Non-invasive in vivo assessment of IDH1 mutational status in glioma
Explore this paper's citation graph
Summary
It is shown that [1-13C] α-ketoglutarate can serve as a metabolic imaging agent for non-invasive, real-time, in vivo monitoring of mutant IDH1 activity, and can inform onIDH1 status.
- Type
- article
- Published
- 2013-09-10
- Cited by
- 134
- References
- 58
- Access
- Open access
- OpenAlex
- https://openalex.org/W2019822930
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:727328
Keywords
Isocitrate dehydrogenase, IDH1, In vivo, Glioma, Mutant
References
- Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI
- Kinetic modeling of hyperpolarized 13C pyruvate metabolism in tumors using a measured arterial input function
- Prospective diagnostic performance evaluation of single‐voxel 1H MRS for typing and grading of brain tumours
- Combined Parallel and Partial Fourier MR Reconstruction for Accelerated 8-Channel Hyperpolarized Carbon-13 In Vivo Magnetic Resonance Spectroscopic Imaging (MRSI)
- Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research.
- Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis.
- Hyperpolarized C‐13 spectroscopic imaging of the TRAMP mouse at 3T—Initial experience
- Molecular subclassification of diffuse gliomas: Seeing order in the chaos
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate
- Feasibility of using hyperpolarized [1-13C]lactate as a substrate for in vivo metabolic 13C MRSI studies.
- 2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping.
- Detection of 2-Hydroxyglutarate in IDH-mutated Glioma Patients by Spectral-editing and 2D Correlation Magnetic Resonance Spectroscopy
- Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors
- Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1-13C]pyruvate and 13C magnetic resonance spectroscopic imaging
- Multiband excitation pulses for hyperpolarized 13C dynamic chemical-shift imaging.
- The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells
- In Vivo13C Spectroscopy in the Rat Brain using Hyperpolarized [1-13C]pyruvate and [2-13C]pyruvate
- Dynamic nuclear polarization polarizer for sterile use intent
- An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Cited by
- Interrogating IDH Mutation in Brain Tumor: Magnetic Resonance and Hyperpolarization
- Conditions for 13C NMR Detection of 2-Hydroxyglutarate in Tissue Extracts from IDH-Mutated Gliomas
- Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme
- Chemical shift encoded imaging of hyperpolarized 13C pyruvate
- Volumetric Spiral Chemical Shift Imaging of Hyperpolarized [2-13C]Pyruvate in a Rat C6 Glioma Model
- Rapid in vivo ADC Mapping of Hyperpolarized 13C Metabolites
- Glial Progenitors as Targets for Transformation in Glioma
- Glioma Cells with the IDH1 Mutation Modulate Metabolic Fractional Flux through Pyruvate Carboxylase
- Hyperpolarized Magnetic Resonance as a Sensitive Detector of Metabolic Function
- Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies.
- Personalized Medicine for Gliomas
- Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance
- Deregulated proliferation and differentiation in brain tumors
- The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
- A Bloch-McConnell simulator with pharmacokinetic modeling to explore accuracy and reproducibility in the measurement of hyperpolarized pyruvate
- Metabolic Reprogramming in Mutant IDH1 Glioma Cells
- Real-time NMR monitoring of biological activities in complex physiological environments.
- 13C-labeled biochemical probes for the study of cancer metabolism with dynamic nuclear polarization-enhanced magnetic resonance imaging
- Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma
- 2-Hydoxyglutarate: D/Riving pathology in gLiomaS
Related papers
- Isocitrate dehydrogenase 1 mutations and human gliomas
- Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
- Inhibition of mutant IDH1 in acute myeloid leukaemia.
- New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status
- Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia
- Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
- Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target
- Metabolism, gliomas, and IDH1.
- Isocitrate dehydrogenase 1and 2 gene mutation status– a critical parameter in the diagnosis and prognosis of adult gliomas
- Isocitrate dehydrogenase mutations in gliomas.